Introduction
============

Remifentanil HCl (R) is a mu-opioid agonist with a rapid onset (∝ 1 min) and offset of action (t1/2 \< 10 min) due to its organ-independent metabolism by non-specific tissue and blood esterases. These properties make it readily titratable and even after prolonged infusion the effects of R do not accumulate. Its major metabolite, remifentanil acid (RA) is eliminated by the kidneys and its elimination is prolonged as a result of increasing renal dysfunction. However RA has been reported to have 1/4600 mu-opioid potency of the parent compound. This study assessed the offset of pharmacodynamic (PD) effects of R in ICU patients with varying degrees of renal dysfunction receiving R for provision of sedation and analgesia.

Methods
=======

R (starting rate 6--9 μg/kg/h) was administered as a continuous infusion for up to 72 hours in 40 ICU patients (10 normal/mild renal impairment, creatinine clearance ≥ 50 ml/min: 30 moderate/severe renal impairment, creatinine clearance \<50 ml/min) who required sedation and analgesia. At scheduled times (8, 24, 48 and 72 hours) R was down titrated until the offset of PD effects (eg changes in sedation, pain intensity, respiratory function or haemodynamic variables) were seen. On confirmation of the offset of PD effects, R was continued at the original rate.

Results
=======

See Table.

       Renal status:           Renal status:
  ---- ----------------------- ------------------------
  8    15.6 ± 7.4 (*n* = 10)   19 ± 15.7 (*n* = 27)
  24   13.8 ± 7.7 (*n* = 10)   20.3 ± 11.7 (*n* = 20)
  48   16.1 ± 7.2 (*n* = 8)    15.4 ± 7.4 (*n* = 12)
  72   14.8 ± 5.7 (*n* = 6)    25.3 ± 12.6 (*n* = 11)

Conclusions
===========

The offset of the PD effects of R were consistent and independent of the duration of infusion even in patients with a significant degree of renal dysfunction. R was well tolerated in these patients. R may therefore be an ideal agent for provision of sedation and analgesia to patients with varying degrees of renal dysfunction in the ICU.
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